# Dose-Response and Pharmacokinetics of Gabapentin Enacarbil (GEn [XP13512 / GSK1838262]) in Restless Legs Syndrome

> **NCT01332305** · PHASE2 · COMPLETED · sponsor: **XenoPort, Inc.** · enrollment: 217 (actual)

## Conditions studied

- Restless Legs Syndrome

## Interventions

- **DRUG:** GEn (XP13512/GSK1838262)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01332305
- **Lead sponsor:** XenoPort, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2008-01
- **Final completion:** 2008-01
- **Target enrollment:** 217 (ACTUAL)
- **Last updated:** 2013-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01332305

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01332305, "Dose-Response and Pharmacokinetics of Gabapentin Enacarbil (GEn [XP13512 / GSK1838262]) in Restless Legs Syndrome". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01332305. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*